1.4500 +0.03 (2.11%)
Pre-Market: 7:06AM EDT
|Bid||1.4000 x 1200|
|Ask||0.0000 x 900|
|Day's Range||1.3805 - 1.5037|
|52 Week Range||0.4500 - 4.5000|
|Beta (5Y Monthly)||4.87|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 09, 2021 - Jul 13, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
IGC got patent (#10,933,082) x its cannabinoid composition & method x treating pain due to Psoriatic Arthritis, Fibromyalgia, Scleroderma & others.
IGC completed administering 1st of 3 levels of dosing of IGC-AD1 on its FDA-approved THC-based phase 1 clinical trial on patients with Alzheimer's.
IGC announced its financial results for the quarter ended December 31, 2020, which is the third quarter of its 2021 fiscal year.